Literature DB >> 21624754

Systemic reactions associated with subcutaneous allergen immunotherapy: timing and risk assessment.

Sigrid Payne DaVeiga1, Xiaobo Liu, Kathleen Caruso, Susan Golubski, Meng Xu, David M Lang.   

Abstract

BACKGROUND: Subcutaneous allergen immunotherapy (SCIT) is associated with risk of systemic reaction. Although risk factors have been identified, the incidence of immunotherapy-related systemic reactions has not changed in recent years.
OBJECTIVES: To examine patterns of systemic reaction and determine whether risk of systemic reaction from SCIT is associated with patterns of response to skin tests to inhalant allergens recorded before receiving SCIT.
METHODS: We carried out a retrospective review from January 2001 to December 2007. Patterns of systemic reaction from immunotherapy were examined. Cases were matched with controls by age (±10 years), sex, and time of injection (±1 week) to determine whether a pattern of more than 33% 3+ and 4+ skin test responses is associated with elevated risk for systemic reaction.
RESULTS: Rate of systemic reaction from SCIT was 0.28% (46/16,375) per injection visit. Twenty patients had 46 systemic reactions. All severe reactions occurred within 30 minutes. The estimated odds of systemic reaction were almost 6 times higher for patients with more than 33% 3 to 4+ positive skin tests (OR = 5.83; 95%CI: 1.23-27.59, P = .026). For each additional 4+ skin test, the estimated odds for systemic reaction increased by 17% (P = .020).
CONCLUSIONS: A small number of patients receiving SCIT account for a large proportion of systemic reactions. Skin test patterns demonstrating a greater number of larger skin tests responses to inhalant skin testing are associated with significantly elevated risk for systemic reaction in patients receiving SCIT.
Copyright © 2011 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21624754     DOI: 10.1016/j.anai.2011.02.007

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  6 in total

1.  Adverse reactions to subcutaneous immunotherapy in patients with allergic rhinitis, a real-world study.

Authors:  Wei Zhang; Yuqin Deng; Huan Tong; Rong Xiang; Shiming Chen; Yonggang Kong; Zezhang Tao; Yu Xu
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-03-13       Impact factor: 2.503

Review 2.  Impact of allergen immunotherapy in allergic asthma.

Authors:  Wenming Zhang; Chunrong Lin; Vanitha Sampath; Kari Nadeau
Journal:  Immunotherapy       Date:  2018-03-23       Impact factor: 4.196

3.  Safety Profile and Issues of Subcutaneous Immunotherapy in the Treatment of Children with Allergic Rhinitis.

Authors:  Anang Endaryanto; Ricardo Adrian Nugraha
Journal:  Cells       Date:  2022-05-09       Impact factor: 7.666

4.  Safety of house dust mite subcutaneous immunotherapy in preschool children with respiratory allergic diseases.

Authors:  Yaqi Yang; Dongxia Ma; Nan Huang; Wenjing Li; Qing Jiang; Yin Wang; Xiaolong Wang; Lin Yang; Rongfei Zhu
Journal:  Ital J Pediatr       Date:  2021-04-23       Impact factor: 2.638

5.  The rate of epinephrine administration associated with allergy skin testing in a suburban allergy practice from 1997 to 2010.

Authors:  David A Swender; Leah R Chernin; Chris Mitchell; Theodore Sher; Robert Hostoffer; Haig Tcheurekdjian
Journal:  Allergy Rhinol (Providence)       Date:  2012-12-12

6.  Systemic Reactions to Dust Mite Subcutaneous Immunotherapy: A 3-Year Follow-up Study.

Authors:  Xiang Dong; Nan Huang; Wenjing Li; Lintao Hu; Xiaolong Wang; Yin Wang; Ning Xiang; Guanghui Liu; Rongfei Zhu
Journal:  Allergy Asthma Immunol Res       Date:  2016-09       Impact factor: 5.764

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.